HONG KONG, Aug. 30, 2018 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the company has been selected by Hang Seng Indexes as a constituent of the Hang Seng HK 35 Index (“HSHK35”) effective 10 September, 2018.

Hang Seng HK 35 comprises the 35 largest companies listed in Hong Kong market which derive the majority of their sales revenue from areas outside mainland China. The Hang Seng HK 35 provides a tradable index reflecting the performance of large-cap Hong Kong companies and it features low volatility which is the best choice for diversification.

WuXi Biologics’ inclusion in HSHK35 signifies that our company is recognized as a global company by the market. Besides China, WuXi Biologics has recently announced plans to execute our globalization strategy to build state-of-the-art manufacturing facilities in Ireland, Singapore and the U.S. WuXi Biologics will continue to focus on expanding our capabilities and capacities to enable our customers to transform biologics discovery, development and manufacturing to benefit patients worldwide.

Prior to joining the Hang Seng HK 35, WuXi Biologics was selected into Hang Seng Composite Index, Hang Seng Healthcare Index and Hang Seng Global Composite Index in September 2017, and was selected into Hang Seng Stock Connect Hong Kong Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng SCHK HK Companies Index and Hang Seng SCHK ex-AH Companies Index in March 2018.

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

View original content:http://www.prnewswire.com/news-releases/wuxi-biologics-selected-into-the-hang-seng-hk-35-index-300704617.html

GORDON, Australia, Aug. 30, 2018 /PRNewswire/ — The American offshoot of Australian biotech Noxopharm, Nyrada, believes it is within reach of achieving a major advance in the treatment of cardiovascular disease. It has made important progress with a drug candidate known as NYX-330 that Nyrada believes may be the next breakthrough medication for heart attack and stroke.

NYX-330 is designed to lower cholesterol levels by inhibiting the action of a protein known as PCSK9 which has become one of the most highly valued targets in the pharmaceutical world since its discovery about 13 years ago. A drug that successfully inhibits this protein has been hailed as potentially rivalling the US$12 billion annual sales a few years ago of the anti-cholesterol drug, Lipitor, the biggest selling drug the world has seen.

PCSK9 has become so important because it is now understood to be the reason why the ‘statin drugs‘, the key cholesterol-fighting drugs, don’t work as well as they should in many people. Having a combined treatment with a statin drug and another drug to block PCSK9 function is what is driving a major race in the pharmaceutical industry to find a PCSK9-inhibitor that doctors and patients will embrace.

Owen Dempsey, US-based executive director of Nyrada and biotech entrepreneur, explained the size of the opportunity, with about 1 in 4 Americans over the age of 45 (about 32 million men and women) now taking statin drugs and accounting for why this is the biggest drug category in the world with combined sales last year of US$19 billion.

“As good as statins are, they can do with extra help to bring cholesterol levels down to ground-floor levels in most people,” he says. “The opportunity we are chasing is a drug that could become a standard co-treatment with statins to deliver those desired levels. A co-treatment to a $19 billion market is a very substantial market.”

Dr Graham Kelly, who is chairman of Nyrada and managing director of Noxopharm, explained the science behind PCSK9. “PCSK9 works by holding cholesterol in the bloodstream, slowing down its removal from the blood,” he says. “That’s a normal function. The problem comes when our bodies make too much PCSK9. The result is reduced clearance resulting in higher cholesterol levels in blood.”

“We now know that one of the consequences of statin therapy is an increase in PCSK9 levels, a normal response on the body’s part to less cholesterol being produced in the body.”

The discovery of PCSK9 in 2005 triggered a major push by the pharmaceutical giants to develop a PCSK9 inhibitor that could be given in conjunction with a statin drug. It was a simple rationale – the statin drug would reduce the amount of cholesterol being made in the body, and the anti-PCSK9 drug would mean that what cholesterol was made would be more readily removed from the blood. A tablet with the same features as the statins – convenient, daily, affordable, oral – was the goal.

That goal hit early snags, with a general switch to developing alternative treatments based on large molecule drugs (monoclonal antibodies), two of which came to market in 2015 – Repatha (Amgen) and Praluent (Regeneron-Sanofi).

“Two very large clinical studies using Repatha or Praluent have now proved that combining them with statins delivers significant health benefits with blood cholesterol levels falling about 60% more than statins alone,” says Dempsey. “But despite that proven benefit, use of these 2 drugs tends to be restricted to very high-risk patients. One reason is practical, with the drugs needing to be injected every 2 or 4 weeks. The second is cost, with a cost for unsubsidised patients of about USD14,000 per year on an ongoing basis. These are not inconsiderable market challenges and we believe that NYX-330 overcomes these challenges.”

Kelly explained the science behind the development of NYX-330. “A private Australian company headed by Dr Ian Dixon and assisted by 3 Australian chemists created the breakthrough,” he says. “Using proprietary drug design software, they identified an area on the PCSK9 molecule that provided a suitable landing site for a small molecule. NYX-330 is the result of that pioneering science.”

“NYX-330 blocks the ability of PCSK9 to bind to the cholesterol receptor. That means more receptors available to remove cholesterol from the blood and that equals lower blood cholesterol levels.

“We are confident that we have a PCSK9 inhibitor with the potential to meet the goals of a convenient, oral, once-daily treatment at an affordable cost.”

NYX-330 currently is undergoing studies in France and elsewhere designed to optimise its function, with an anticipated 15-18 months before it will be ready to bring into the clinic.

Nyrada Inc is a US-based biotechnology company. It was spun out of Noxopharm in 2017 to take advantage of the interest of the US capital market in biotech investment. Noxopharm currently owns 67% of Nyrada and Dr Dixon, through an investing entity, currently owns 33% of Nyrada. Senior management, including a chief executive officer and board, will be based in the US. Nyrada raised A$4 million through Australian 708(8) investors in February 2018.

View original content:http://www.prnewswire.com/news-releases/lower-cholesterol-treatment-breakthrough-300704639.html

• Anti-cancer effect proved by research team of Kangwon National University’s Professor Jang Ae-ra
• Expected to help dispel misunderstanding that red meat expedites colorectal cancer

SEOUL, South Korea, Aug. 29, 2018 /PRNewswire/ — A recent study has shown that Korean beef (Hanwoo) inhibits the proliferation of colorectal cancer cells.

Korean beef (Hanwoo) inhibits the proliferation of colorectal cancer cells

On August 29, the research team of Kangwon National University’s Professor Jang Ae-ra, in their study appointed by Hanwooboard and entitled “Study on changes in phytonutrients in Korean beef and their influence on the inhibition mechanism for colorectal cancer,” proved that the phytonutrients in Korean beef (carnosine and L-carnitine) inhibit the proliferation of colorectal cancer cells.

The research team explained that carnosine is a substance that changes the growth cycle of colorectal cancer cells, thus preventing them from increasing in number, while L-carnitine expedites the growth of active oxygen species inside colorectal cancer cells, which generates increased stress levels inside the cells and thus ends up preventing the proliferation of colorectal cancer cells. The research added that both substances are present in Korean beef in quantities higher than beef from other countries (United States, Australia, etc.).

The research team investigated the effects of Korean beef consumption on colorectal cancer by injecting a test animal (mimicking the body conditions of a 60-kilogram adult) with a fluid prepared from Korean beef (low concentration: 57 grams, high concentration: 115 grams) on a daily basis for six weeks. It was found that the colorectal cancer of the test animal did not worsen, even when the highly concentrated fluid was administered, but instead showed improved lipid metabolism and an alleviation of colitis via the increased activity of antioxidants within the large intestine.

Chang’s team also discovered that, upon injecting peptides from Korean beef into the test animal, there was a noticeable improvement in colorectal cancer symptoms (increase in beneficial microorganisms and decrease in harmful bacteria within the intestine), despite the relatively short period over which the injections were administered (seven days).

The aim of the study was to convey accurate information on Korean beef to consumers by uncovering the changes in phytonutrients in Korean beef; conducting a scientific investigation of the influence of such phytonutrients on colorectal cancer; and the efficacy of anti-cancer treatments.

Hanwooboard Chairman Min Gyeong-cheon said, “The study by the Kangwon National University team clearly shows that colorectal cancer is not caused by the consumption of red meat per se but rather is attributable to a diverse range of factors, including stress, alcohol consumption, cigarette smoking, and a high-sodium diet.”

Photo – https://photos.prnasia.com/prnh/20180824/2220224-1

Source: KinoPharma, Inc., National Institutes for Quantum and Radiological Science and Technology

SUZHOU, China, Aug. 27, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) announced today that its IND application for CS1002, an investigational cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) monoclonal antibody, has been approved by the China National Drug Administration (CNDA).

“We are very pleased to obtain our third China IND approval of our investigational drugs in 2018. CStone already initiated CS1002’s Phase I clinical trial in Australia and dosed the first patient in May.” said Dr. Frank Jiang, Chairman and Chief Executive Officer of CStone. ” With today’s IND approval of CS1002, CStone is currently the only biopharmaceutical company in China that has all three immuno-oncology ‘backbone’ products (anti-PD-L1, anti-PD-1, and anti-CTLA-4 mAbs) in the clinical stage.”

“CS1002 has demonstrated a high level of selectivity, specificity and high affinity to CTLA-4 in preclinical studies,” said Dr. Jingrong Li, Senior Vice President of Product Development and Manufacture at CStone. “Combination therapies of anti-CTLA-4 mAb with anti-PD-1 mAb have demonstrated promising efficacy in multiple tumor types by global clinical trials. CStone will explore combination potentials between CS1002 and other drug candidates in our pipeline to provide better therapies for cancer patients in China and beyond.”

As of today, CStone has built a portfolio of 14 oncology products, 8 of which are at clinical development stage, including 3 in registration studies. CS1001, China’s first fully human, full-length anti-PD-L1 mAb developed by CStone, has entered pivotal Phase II clinical studies, and will potentially become one of the first locally-developed anti-PD-L1 cancer drugs launched in China. In June 2018, CStone announced the exclusive collaboration and license agreements with Blueprint Medicine and Agios Pharmaceuticals. With these two deals, CStone in-licensed 4 post proof of concept assets, including ivosidenib, which is recently approved by U.S. FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, and avapritinib, which has entered global Phase III clinical studies.

About the CTLA-4 pathway

Cytotoxic T lymphocyte associated antigen 4 (CTLA-4), also known as CD152, is a transmembrane protein encoded by the CTLA-4 gene that can down-regulate the activity of T cells when binding with its ligands, B7.1 and B7.2, a pathway also used by tumor cells to avoid T lymphocyte attack. Consequently, blockade of the CTLA-4 pathway can stimulate T cell activation and proliferation to induce or enhance anti-tumor immune responses. CTLA-4 provides a new immuno-therapeutic approach to a number of diseases, including tumors.

Presently, Bristol-Myers Squibb’s Yervoy (ipilimumab) is the only anti-CTLA-4 antibody to gain a market approval worldwide, although Yervoy has not yet been approved in China. Pre-clinical tests have shown that CS1002 has a relatively strong affinity to CTLA-4 and is expected to match Yervoy in terms of efficacy.

About CStone Pharmaceuticals

CStone Pharmaceuticals is a clinical stage biopharmaceutical company devoted to the development of innovative drugs. With a broad pipeline, the company engages in the development of cancer therapeutics with a special focus on immuno-oncology based combination therapies. All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up its core competency in clinical development and translational medicine. The company is backed by prestigious VC/PE funds via two financing rounds to date, raising $150 million in a Series A round in July 2016, followed by $260 million in a Series B round in May 2018. With an experienced team, a rich pipeline, a robust R&D model, and substantial funding, CStone is well positioned as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia-Pacific region.

For more information about CStone Pharmaceuticals, please visit:
www.cstonepharma.com

View original content:http://www.prnewswire.com/news-releases/cstones-anti-ctla-4-antibody-cs1002-receives-ind-approval-in-china-300703022.html

U.are.U® and TouchChip Sales Exceed 750,000 in Unit Sales

PALM BEACH GARDENS, Florida, Aug. 28, 2018 /PRNewswire/ — Crossmatch®, a globally-recognized leader in biometric identity management and secure authentication solutions, announced today that sales of its silicon and optical single finger readers, modules and sensors in India surpassed 750,000 units, primarily through its Indian partner AqTronics Technologies and their affiliates.

The company’s silicon-based TouchChip line of readers, modules and sensors provide a low profile and small footprint for OEM device integration. Fingerprint images are captured at the well-established native 500 ppi standard as required by the Standardization Testing and Quality Certification (STQC) and FBI. This ensures the ability to capture digital imaging at the highest commercial resolution, providing the broadest range of finger features including those of the very young and old, which results in fast, accurate matching performance for mission critical Aadhaar applications. 500 ppi is also the native resolution at which fingerprints were initially enrolled in the Aadhaar program, as mandated by STQC, further enhancing match speed and accuracy.

The TouchChip line includes touch and swipe sensor configurations, as well as a chipset model for on-device matching. Surface coating options are also available for added durability in extremely high volume and/or harsh environment use cases. It is estimated that Crossmatch biometric modules are embedded in approximately 50% of the fingerprint-enabled point-of-sale devices in the market.

Like the TouchChip line, U.are.U® 500 ppi optical fingerprint readers and modules provide fast, high-quality fingerprint image capture for a wide range of skin conditions, are easy to use and are offered at economical price points. A robust software development kit (SDK) enables developers to rapidly integrate the benefits of fingerprint biometrics for assured identity.

“India represents an important market for the company,” noted John Hinmon, marketing lead for Crossmatch. “Through our valued local partners and distributors, the U.are.U and TouchChip lines are sold for use in a wide range of applications, including secure transaction authentication, supported by the Unique Identification Authority of India (UIDAI) Aadhaar program.”

Crossmatch is currently in the UIDAI Biometric Authentication Devices – L1 – Registered Device certification process with its TCS1 line of biometric readers, modules and sensors. The L1 – Registered Device certification is to be used by all Authentication Eco partners in India.  Crossmatch was awarded L0 – Registered Device certification in September 2017.

Registered device certification refers to devices that are registered with the Aadhaar system for encryption key management. The Aadhaar authentication server can individually identify and validate these devices and manage encryption keys on each registered device.

As one of the original UIDAI STQC certified biometric capture device vendors, Crossmatch has a long history of providing high-performing biometric enrollment and verification devices in support of Aadhaar. 

About Crossmatch

Crossmatch® solutions solve security and identity management challenges for hundreds of millions worldwide. Our DigitalPersona® composite authentication software protects enterprise using an optimal set of authentication factors, designed to meet today’s unique risk requirements. Crossmatch also delivers high performing, trusted biometric identity management hardware and software for critical applications. Serving financial, retail, commercial, government, law enforcement and military markets in over 80 countries, Crossmatch sets the standard for innovation and reliability. Learn more: Crossmatch.com.

Logo – https://mma.prnewswire.com/media/367963/Crossmatch___Logo.jpg

CHONGQING, China, Aug. 27, 2018 /PRNewswire/ — From artificial throats helping the deaf or hard of hearing to “speak”, to electronic skin that can feel hot, cold and pain, 10 mind-boggling tech products were launched at the first Smart China Expo (SCE 2018) that opened this week in China’s western city of Chongqing.

10 Mind-boggling Tech Products Launched at SCE 2018 in Chongqing.

Referred to as “Cool tech”, or “Black Technology” in China, these amazing products – also including self-driving new energy vehicles (NEVs) and Nano-Robots used in hospitals — stood out as the embodiment of the phenomenal achievements humankind has made to date.

Under the theme of “Mind-boggling technologies: the “Unimaginable Future,” the ten featured futuristic products were selected from 1,082 candidates following three rounds of strict reviews by experts from a variety of sectors, including universities, enterprises, and venture capital firms. The newly released list gives SCE visitors a glimpse of how many aspects of our lives could be shaped by technology in the not too distant future.

Additional ground-breaking technologies launched during the event also included:

• Laser-Induced Graphene (LIG) Artificial Throat by Tsinghua University
• Highly stretchable and expandable E-skin by Beijing Institute of Nanoenergy and Nanosystems
• L4 Autonomous NEV by Changan Automobile
• Nano-Robots in Medicine by the Harbin Institute of Technology and University of California, San Diego
• Thought-controlled neuroprosthesis by The Shenzhen Institute of Advanced Technology
• Dissolvable electronic components by Zhejiang University
• AI Medical Innovation System (AIMIS) by Tencent
• iFLYTEK mobile translator 2.0 by iFLYTEK
• Person Re-Identification (REID) system by CloudWalk Technology
• ET Industrial Brain by Alibaba Cloud.

Some of these products have already been brought to market, while others are still in the R&D process.

SCE also played host to competitions including the International Drone Racing Grand Prix (IDRGP) and i-VISTA autonomous car racing.

The side events at SCE also highlights host city, Chongqing’s ambition to become China’s pioneer in Big Data Intelligence, as well as the city’s willingness to attract talents and investments in the field of smart technology to the region.

“Chongqing has adopted an innovation-led growth strategy that will breathe new life into its traditional industries with the help of Big Data Intelligence, and will maximize commercial, governmental and civil use of technology,” said Tang Liangzhi, mayor of Chongqing. “Holding SCE is a key step toward developing smart technologies, and we expect to deepen our cooperation with partners all over the world and jointly create a better future under the theme of ‘Smart Technology: Empowering the Economy and Enriching Life'”.

For more information, please visit https://www.smartchina-expo.cn/ and http://www.ichongqing.info/smart-china-expo/

About Smart China Expo (SCE)

Held in Chongqing, the Smart China Expo (SCE) is a world-class, national-level Expo that supports the development of big data and smart technologies in Western China. SCE serves as a platform for Chongqing’s Smart Endeavors in the era of big data and smart tech, as well as for exchanges among organizations, enterprises, experts and scholars from around the world. 

IDRGP, one of the most influential drone racing event in the world has been brought to the SCE.

Photo  – https://photos.prnasia.com/prnh/20180827/2220830-1-a
Photo  – https://photos.prnasia.com/prnh/20180827/2220830-1-b

• Cold Defence™ is a natural product with anti-viral effects that helps to eliminate 99% of cold and flu viruses and shorten the duration of common colds.   
• First launched in Asia in 2017, the over-the-counter treatment is already available in more than 12 countries as part of Mundipharma’s BETADINE^® range of consumer healthcare products.

SINGAPORE, Aug. 27, 2018 /PRNewswire/ — Mundipharma will be introducing Cold Defence™, a new early treatment hailed as a “world-first” [i], in Turkey and Canada to help families stay healthy and fight the common cold.

Professor Ronald Eccles, who established the Common Cold Centre at Cardiff University in 1988 and has been involved in over 120 clinical trials for over 30 years, said “This is one of the most exciting developments I’ve ever seen,” and described it as “safe and effective”.[ii]

Common cold and flu-like illnesses are viral infections that affects adults twice per year on average. The impact is greater for children who can typically contract them up to five to seven times per year due to their close proximity at school and play.

Clinical trials have shown that this treatment reduced duration of disease by up to two days for children, and by two days for adults, increased viral clearance and reduced severity of cold and flu-like symptoms.

Cold Defence™ is a natural product with anti-viral effects that helps reduce duration of colds in adults and children. It is delivered as a nasal spray and contains the ingredient iota-carrageenan, also called Carragelose^®. It is available in adult and children’s formulations and is recommended for use at the first sign of cold and flu-like symptoms.

Several large scale clinical trials involving close to 600 adult and paediatric patients were conducted to evaluate the efficacy and safety of the product. The analysis of children and adults suffering from virus-confirmed common cold after two randomized, double-blind, placebo-controlled trials demonstrated that it appeared as an effective treatment of common cold [iii],[iv]

Mundipharma CEO, Raman Singh, said “Every year the common cold interrupts family, school and working life, soaking up medical leave, putting pressure on productivity and colleagues and interrupting people’s daily life. As an early treatment to manage the Cold and other flu-like illnesses, Cold Defence™ can help keep families and workplaces productive and healthy.“

“Providing Cold Defence™ in Canada and Turkey continues our commitment to the day-to-day wellbeing of families.”

About Mundipharma

Mundipharma is a network of independent associated companies, which are privately owned entities, covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.

For more information please visit: www.mundipharma.com.sg

®: BETADINE is a Registered Trademark of Mundipharma.

®: Carregelose is a Registered Trademark of Marinomed.

Registered indications differ country to country hence please check with a local Mundipharma office for more information on the local approved prescribing information.

Logo – http://photos.prnasia.com/prnh/20150302/8521501264LOGO

SHANGHAI, Aug. 22, 2018 /PRNewswire/ — WuXi AppTec (603259.SH), a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Mr. Edward Hu as Co-CEO of the company. Mr. Hu will continue to report to Dr. Ge Li, Chairman and CEO of WuXi AppTec.

As the company’s Co-CEO, Mr. Hu will share business management responsibilities with Dr. Li, including the small molecule drug discovery, development, manufacturing services, drug and medical device testing services, etc. Mr. Hu will continue to act as the CFO in charge of corporate finance, investment, and mergers and acquisitions, until a new CFO comes on board.

Since joining WuXi in 2007, Mr. Hu has served as the company’s Chief Operating Officer, and later Chief Financial Officer and Chief Investment Officer. Over the past decade, he has scored significant achievements in operational excellence, financial management, and WuXi’s global business expansion. Mr. Hu was elected to the Board of Directors in March 2016.

“Ed’s extraordinary business leadership has been, and will continue to be critical to the growth of WuXi AppTec,” stated Dr. Ge Li, Chairman and CEO of WuXi AppTec. “I look forward to working closely with Ed as we enter an exciting new era of growth, and please join me in wishing him even greater success in his new role.”

“I’m very grateful for the trust placed in me by the board and Dr. Li,” said Mr. Hu. “It’s our vision to enable anyone and any company to realize their R&D dream, so that patients can benefit from earlier access to better medicines. Together, we will strive to fulfill WuXi’s dream that every drug can be made and every disease can be treated.”

Prior to WuXi, Mr. Hu served as Senior Vice President and Chief Operating Officer at Tanox.

His earlier career spanned managerial and financial positions at Biogen and Merck respectively. Mr. Hu has an MBA and Master’s degree in Chemistry from Carnegie Mellon University.

About WuXi AppTec

WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our customers and partners worldwide shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, the WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”  Please visit: http://www.wuxiapptec.com

View original content with multimedia:http://www.prnewswire.com/news-releases/wuxi-apptec-appoints-edward-hu-as-co-ceo-300700822.html